Company: TAK
Filing Date: 2025-06-06
Form Type: 6-K
Source: 0001395064-25-000076
Chunk: 2

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-06
Form: 6-K
Chunk 2
---
 in a peer group of global pharmaceutical companies and establishes compensation and performance targets that closely link pay with performance and long-term shareholder value creation. A significant proportion of the Internal Directors’ compensation is in the form of stock-based long-term incentives, which include a Total Shareholder Returns modifier, thereby closely linking management compensation to the shareholder experience.

We believe that important data readouts in 2025 from our high-potential late-stage pipeline will lead to increased investor confidence in Takeda’s long-term growth potential, and that this in turn should be reflected in the company’s valuation over time.

The Board and I have full confidence in Christophe Weber as President & CEO, and in his ability to execute the company’s strategy towards maximizing long-term shareholder value. We also believe it is critical that he is given time to execute a smooth and successful transition to Julie Kim, who will succeed Mr. Weber as President & CEO and will be proposed as a candidate for election to the Board of Directors in June 2026.

Meanwhile, the Board will strive to continue to improve Takeda's corporate value through strict and appropriate oversight.

We therefore respectfully request that shareholders vote in favor of all Company proposals at the 149th Annual General Meeting of Shareholders.

Masami Iijima

Chair of the Board Meeting

Takeda Pharmaceutical Company

#### Takeda Important Notice
For the purposes of this notice, “statement” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this statement. This statement (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this statement. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This statement is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute